Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Information source: National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma
Intervention: Lenalidomide (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Georg Aue, M.D. Official(s) and/or principal investigator(s): Georg Aue, MD, Principal Investigator, Affiliation: NIH National Heart, Lung and Blood Institute
Summary
This study will evaluate the safety and effectiveness of a new drug called lenalidomide
(Revlimid) for treating patients with chronic lymphocytic leukemia (CLL) and small
lymphocytic lymphoma (SLL) who relapsed after their initial treatment.
Patients 21 years of age and older with CLL or SLL who have previously received standard
treatment may be eligible for this study.
Participants take lenalidomide capsules once a day for 21 days, followed by 21 days off the
drug. This constitutes one treatment cycle. Treatment continues for four cycles as long as
the medicine is tolerated. After four cycles, patients who respond completely continue
treatment for another two cycles; patients who respond partially continue treatment for
another four cycles; and patients who do not respond stop treatment but continue to be
followed for safety.
...
Clinical Details
Official title: A Phase II Study of Lenalidomide Revlimid(Registered Trademark) in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: To Establish the Overall Response Rate Measured at 24 Weeks After First Dose of Lenalidomide Using This Dosing Regimen
Detailed description:
There is evidence that lenalidomide has single agent activity in chronic lymphocytic
leukemia (CLL)/small lymphocytic leukemia (SLL). Optimal dosing of lenalidomide in CLL has
not been established yet. A pilot clinical trial in CLL studied single agent lenalidomide
cycled every 4 weeks with 25 mg for three weeks on and one week off drug. In this trial dose
reductions have been necessary secondary to prolonged neutropenia or thrombocytopenia in a
majority of patients. However, there was also remarkable efficacy and evidence for an immune
stimulatory effect of lenalidomide. Therefore, we propose this phase II trial using 20 mg
lenalidomide (Revlimid(Registered Trademark)) 3 weeks on and 3 weeks off for 4 cycles in
subjects who have been previously treated for chronic lymphocytic leukemia (CLL)/small
lymphocytic leukemia (SLL). Subjects with at least partial response (PR) may go on to
receive 4 additional cycles.
The primary objective of the trial is to test the efficacy of a more tolerable dosing scheme
of lenalidomide.
Eligibility
Minimum age: 21 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
- INCLUSION CRITERIA:
1. Diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia
(SLL).
2. Failed prior standard of care therapy for CLL.
3. Neutrophil count (ANC) greater than or equal to 500/microliter (mcL).
4. Platelet count greater than or equal to 20,000/mcL.
5. Age 21-99.
EXCLUSION CRITERIA:
1. Chronic or current clinically significant infection, including HIV positivity or
uncontrolled infection.
2. Eastern Cooperative Oncology Group (ECOG) performance greater than 2.
3. Other concurrent anticancer therapies.
4. Less than 4 weeks from last systemic therapy for CLL. Steroids up to 2 weeks before
the start of treatment are permissible.
5. Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary,
infectious, or metabolic disease of such severity that it would preclude the
patient's ability to tolerate protocol therapy.
6. Creatinine greater than 1. 5 times the upper limit of normal.
7. Women who are pregnant or nursing, as well as women of childbearing potential who are
unwilling to use a dual method of contraception.
8. Men who are unwilling to use a barrier protection.
9. Inability to understand the investigational nature of the study; inability to provide
informed consent.
Locations and Contacts
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland 20892, United States
Additional Information
NIH Clinical Center Detailed Web Page
Starting date: February 2007
Last updated: November 14, 2013
|